Update on Mantle Cell Lymphoma – August 28, 2024
Featuring: Dr. Rahul Lakhotia, National Cancer Institute
Category Mantle Cell Lymphoma
Ran Xu, PhD
Researcher Spotlight: Ran Xu, PhD DANA FARBER CANCER INSTITUTE Many patients with mantle cell lymphoma (MCL) achieve complete remission with novel chimeric antigen receptor (CAR) T cell therapies, but some cancer cells remain that may eventually lead to relapse. Using…
Lydie Debaize, PhD
Researcher Spotlight: Lydie Debaize, PhD Dana-Farber Cancer Institute Most patients treated for mantle cell lymphoma (MCL)achieve complete remission. Nevertheless, a significantnumber of patients will eventually relapse due to theregrowing of rare cancer cells remaining in the bodyafter treatment, which is known…
Christina Lee, MD
Researcher Spotlight: Christina Lee, MD Memorial Sloan Kettering Cancer Center It has become increasingly apparent that normal immune cells are important in disease progression and therapy resistance in lymphoma. Studies from a clinical trial of two targeted therapies, ibrutinib (Imbruvica)…
Allison Rosenthal, DO
Researcher Spotlight: Allison Rosenthal, DO Mayo Clinic Arizona Mantle cell lymphoma (MCL) can present in a variety of ways, from slow-growing indolent to more aggressive forms with poorer outcomes. Currently a patient’s treatment plan is largely based on patient age…
Jianguo Tao, MD, PhD
Researcher Spotlight: Jianguo Tao, MD, PhD H. Lee Moffitt Cancer Center With the success of ibrutinib in mantle cell lymphoma (MCL) and other B-cell lymphomas, researchers have become focused on the problem of treatment resistance – not only do a…
Sandeep Dave, MD, MS
Researcher Spotlight: Sandeep Dave, MD, MS Duke University Medical Center “Even as progress has been made in a number of cancers, the options for MCL patients remain disappointingly narrow,” says Dr. Dave. He and his colleagues are seeking to expand…